Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127049991 | 12704999 | 1 | I | 20160829 | 0 | 20160831 | 20160831 | DIR | 45.00 | YR | F | N | 71.10000 | KG | 20160830 | N | PH | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127049991 | 12704999 | 1 | PS | HYDROXYZINE | HYDROXYZINEHYDROXYZINE HYDROCHLORIDE | 1 | Oral | D | D | 0 | 25 | MG | PRN | ||||||
127049991 | 12704999 | 2 | SS | SOTALOL. | SOTALOL | 1 | Oral | D | D | 0 | 80 | MG | BID | ||||||
127049991 | 12704999 | 4 | C | ZYRTEC | CETIRIZINE HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127049991 | 12704999 | 1 | Urticaria |
127049991 | 12704999 | 2 | Ventricular tachycardia |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127049991 | 12704999 | HO |
127049991 | 12704999 | LT |
127049991 | 12704999 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127049991 | 12704999 | Cardiac arrest | |
127049991 | 12704999 | Torsade de pointes | |
127049991 | 12704999 | Ventricular fibrillation |
Reporting Sources (this data is often not reported and may therefore be missing here)
Event ID | CASEID | RPSR COD |
---|---|---|
127049991 | 12704999 | HP |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127049991 | 12704999 | 2 | 20151007 | 20160829 | 0 |